Tardive Dyskinesia (TD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Tardive Dyskinesia (TD) Market Outlook
Thelansis’s “Tardive Dyskinesia (TD)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Tardive Dyskinesia (TD) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Tardive
Dyskinesia (TD) Overview
Tardive
dyskinesia (TD) is a neurological movement disorder that develops as a
complication of long-term use of dopamine receptor–blocking agents, most
commonly antipsychotic medications. It is characterized by involuntary,
repetitive movements that often affect the face, tongue, lips, and jaw, such as
grimacing, chewing motions, or tongue protrusion, and may also involve the
trunk and limbs. The condition arises from chronic dopamine receptor
hypersensitivity in the basal ganglia, leading to abnormal signaling and motor
control. TD can be socially and functionally disabling, with symptoms
persisting even after discontinuation of the causative drug. Diagnosis is made
through clinical evaluation, identifying typical movements in consideration of
the patient’s medication history. Management strategies involve several key
actions: reducing or discontinuing the offending agent whenever possible,
switching to lower-risk antipsychotics, and utilizing approved treatments such
as vesicular monoamine transporter 2 (VMAT2) inhibitors, which can help reduce
abnormal movements. Early detection and intervention are crucial for improving
patient outcomes and minimizing long-term disabilities.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment